Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Deferred Taxes (2022 - 2025)

Historic Deferred Taxes for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $255000.0.

  • Centessa Pharmaceuticals' Deferred Taxes fell 7966.51% to $255000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 2697.06%. This contributed to the annual value of $2.7 million for FY2024, which is 11000.04% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Deferred Taxes stood at $255000.0, which was down 7966.51% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Deferred Taxes registered a high of $1.3 million during Q3 2024, and its lowest value of -$23.5 million during Q2 2023.
  • For the 4-year period, Centessa Pharmaceuticals' Deferred Taxes averaged around -$2.0 million, with its median value being $326500.0 (2024).
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Deferred Taxes plummeted by 204074.07% in 2023, and later skyrocketed by 36711.41% in 2024.
  • Centessa Pharmaceuticals' Deferred Taxes (Quarter) stood at -$2.8 million in 2022, then surged by 94.63% to -$149000.0 in 2023, then surged by 367.11% to $398000.0 in 2024, then plummeted by 35.93% to $255000.0 in 2025.
  • Its Deferred Taxes stands at $255000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $995000.0 for Q1 2025.